BOSTON--(BUSINESS WIRE)--Invicro, LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, today announced the hiring of Mr. George Abe, as Senior Vice President of Pathology.
Backed by more than 25 years of technology and life science business experience, Mr. Abe will lead and expand Invicro’s global pathology services. Under Konica Minolta Inc.’s (Konica Minolta) recent acquisition and with the Ambry Genetics partnership, Invicro will now have a full-suite of precision medicine capabilities that will offer customers advanced scientific insights into disease diagnosis and targeted therapy development.
“We are very excited to have George join the Invicro team,” said Dr. Jack Hoppin, CEO and Co-Founder of Invicro. “Throughout his career, George has demonstrated entrepreneurial leadership focused on solving customer problems while building strong teams and delivering financial value. Along with his background in leading life science imaging organizations, George is ideally suited to help lead our efforts in providing solutions and services to enable precision medicine. He will play a key role in building our pathology business to scale with value-added imaging solutions and services.”
Prior to joining Invicro, Mr. Abe was President and CEO of Cubresa, a molecular imaging company, since 2015. From 2011 to 2014, he was President of Emerald Biosystems and Biostructures, a structural biology technology provider and contract research organization. Prior to that, from 2002 to 2010, Mr. Abe was President and CEO of quantitative tissue imaging and digital pathology pioneer, Cambridge Research and Instrumentation (CRi), now part of PerkinElmer. He has also served on various public, private, and not for profit boards.
“I have known Jack and the Invicro team for some time. They are truly world class innovators, with a reputation in the market for deep scientific understanding blended with unwavering customer focus,” said Mr. Abe. “With the capabilities and resources of Konica Minolta and our partner organization Ambry Genetics, we are extremely well positioned to provide integrated multi-modal scientific services to our customers. Konica Minolta’s High Sensitivity Tissue Testing (HSTT) technology will change the way quantitative immunohistochemistry is performed. Further, the bio-informatics expertise and resources that the combined businesses have assembled are unparalleled. I look forward to leading the team that is expanding the company’s translational imaging offerings into pathology.”
Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017. Now through preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®, has inspired a strong and growing presence in the market. For more information, visit www.invicro.com
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers, and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/